Avonex: Phase III data; marketed to treat relapsing-remitting MS

Subset analysis of the 383-patient North American Phase III CHAMPS trial showed Avonex decreased the risk of progression to CDMS by 66% compared to placebo. The subgroup consisted of 91 individuals wi...